NASDAQ$VRNA
Verona Pharma plc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Verona Pharma reported its financial results and provided a corporate update for the first quarter of 2021.
Verona Pharma announced its Q1 2021 financial results, highlighting the ongoing patient recruitment for the Phase 3 ENHANCE clinical program and expecting to complete enrollment in both studies in the second half of 2021. They also reported results from two clinical studies and strengthened their board with the appointment of Lisa Deschamps.
- Patient recruitment is ongoing in Phase 3 ENHANCE clinical program, with completion expected in 2H21.
- Top-line data from ENHANCE-2 is expected in the first half of 2022, and from ENHANCE-1 in the second half of 2022.
- Positive Phase 2 results were reported with the pMDI formulation of ensifentrine in moderate to severe COPD patients.
- A pilot study showed pMDI ensifentrine added to standard of care was well tolerated in patients hospitalized with COVID-19, though no benefit was observed.
Headline financials
Revenue & EPS history
Verona Pharma · Revenue · Quarterly
$103M
Forward guidance
Verona Pharma is focused on completing enrollment in the Phase 3 ENHANCE program and reporting top-line data from the studies in 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+3.3%
Avg return
Earnings day
+7.2%
Avg return
5 days after
+5.6%
Avg return
30 days after
48%
12 / 25 earnings
Positive
+56.8%
Q2 2022
Best reaction
-14.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | -0.0% | -0.1% | +0.9% | |
| Q1 2025 | +6.4% | +5.6% | +12.5% | |
| Q4 2024 | +5.7% | +6.4% | +1.5% | |
| Q3 2024 | +9.7% | +10.2% | +14.0% | |
| Q2 2024 | +15.8% | +36.5% | +35.1% | |
| Q1 2024 | -0.2% | -6.8% | -18.4% | |
| Q4 2023 | +5.4% | -1.1% | -6.4% | |
| Q3 2023 | +7.6% | — | — | |
| Q2 2023 | -3.4% | — | — | |
| Q1 2023 | +7.1% | — | — | |
| Q4 2022 | -8.5% | — | — | |
| Q3 2022 | -5.8% | — | — | |
| Q2 2022 | +56.8% | — | — | |
| Q1 2022 | +3.8% | — | — | |
| Q4 2021 | -1.1% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q2 2021 | +3.9% | — | — | |
| Q1 2021 | -4.4% | — | — | |
| Q4 2020 | -0.1% | — | — | |
| Q2 2020 | +10.3% | — | — | |
| Q4 2019 | -14.7% | — | — | |
| Q4 2018 | -3.3% | — | — | |
| Q3 2018 | +2.1% | — | — | |
| Q4 2017 | -3.5% | — | — | |
| Q3 2017 | -4.2% | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro